UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,846	06/06/2002	John Carter	3920-0110P	5250
James W. Helly	7590 09/01/200 vege	EXAMINER		
Muncy, Geissler, Olds & Lowe, PLLC			CHOI, FRANK I	
P.O. Box 1364 Fairfax, VA 22038-1364			ART UNIT	PAPER NUMBER
•			1616	
			MAIL DATE	DELIVERY MODE
			09/01/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/089,846	CARTER, JOHN			
Office Action Summary	Examiner	Art Unit			
	FRANK I. CHOI	1616			
The MAILING DATE of this commun Period for Reply	ication appears on the cover sheet w	ith the correspondence address			
A SHORTENED STATUTORY PERIOD F THE MAILING DATE OF THIS COMMUNI - Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this comn - If the period for reply specified above, the maximum state - Failure to reply within the set or extended period for reply Any reply received by the Office later than three months a earned patent term adjustment. See 37 CFR 1.704(b).	ICATION. of 37 CFR 1.136(a). In no event, however, may a nunication. 10) days, a reply within the statutory minimum of thir attutory period will apply and will expire SIX (6) MON will, by statute, cause the application to become Al	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) file	ed on <i>12 August 200</i> 9.				
	· · · · · · · · · · · · · · · · · · ·				
3)⊠ Since this application is in condition	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practi	ce under <i>Ex parte Quayl</i> e, 1935 C.D). 11, 453 O.G. 213.			
Disposition of Claims					
4)	re withdrawn from consideration. 130,132-135,165 and 166 is/are allocation is a second requirement.				
, <u> </u>	9)⊠ The specification is objected to by the Examiner. 10)⊠ The drawing(s) filed on <u>04 April 2002</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.				
Applicant may not request that any object					
		g(s) is objected to. See 37 CFR 1.121(d).			
11)☐ The oath or declaration is objected to	by the Examiner. Note the attache	d Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
2. ☐ Certified copies of the priority3. ☒ Copies of the certified copies	documents have been received. documents have been received in A of the priority documents have been	Application No n received in this National Stage			
Attach weart(a)					
Attachment(s) 1) Notice of References Cited (PTO-892)	4) 🖂 Interview	Summary (PTO-413)			
Notice of References Cited (F10-592) Notice of Draftsperson's Patent Drawing Review (F3) Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date	PTO-948) Paper No((s)/Mail Date Informal Patent Application (PTO-152)			

Art Unit: 1616

DETAILED ACTION

Specification

The abstract of the disclosure is objected to because the current Abstract is not descriptive of the claimed invention in that the claimed invention is directed to a method of treating neoplastic disease and includes copper orotate or copper gluconate, sodium salicylate, Vitamin C and manganes gluconate or manganese orotate and optionally one or more of iron gluconate or iron orotate, sublimed sulphur and zinc gluconate or zinc orotate as the sole pharmaceutically active ingredients, whereas the original abstract is only directed to a composition which is can include other pharmaceutically active ingredients, does not mention orotate or gluconate salts, manganese or sodium salicylate. Correction is required. See MPEP § 608.01(b).

The title of the invention is not descriptive in that "pharmaceutical compositions and their use" so broad as to be meaningless with respect to the claimed invention as indicated above. A new title is required that is clearly indicative of the invention to which the claims are directed.

Conclusion

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier number for accessing the facsimile machine is 571-273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Choi whose telephone number is (571)272-0610. Examiner maintains a compressed schedule and may be reached Monday, Tuesday, Wednesday and Thursday, 6:00 am -4:30 pm (EST).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Johann R. Richter, can be reached at (571)272-0646. Additionally, Technology Center 1600's Receptionist and Customer Service can be reached at (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Application/Control Number: 10/089,846 Page 3

Art Unit: 1616

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Frank Choi Patent Examiner Technology Center 1600 September 1, 2009

/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1617